Federal Circuit Affirms District Court Judgment of Non-Infringement for Piramal


McAndrews client Piramal Healthcare filed an Abbreviated New Drug Application (ANDA) to market a generic version of Sensipar (cinacalcet), a drug for treating hyperparathyroidism in patients on dialysis. Amgen, the maker of Sensipar, responded by filing suit against Piramal for patent infringement.

McAndrews represented Piramal in the case, which went to trial in Delaware in March 2018. In July 2018, the court ruled in Piramal’s favor, finding that Piramal’s generic cinacalcet product does not infringe any of the asserted claims of Amgen’s patent. Today, the Federal Circuit affirmed the district court judgment of non-infringement. The McAndrews team included Shareholders Aaron Barkoff and Alex Menchaca. Click here to view the opinion.